TheraCryf
Mobile close button Mobile toggle button
Hexagon-pattern

Welcome to TheraCryf plc

Developing innovative therapeutics in oncology and behavioural brain disorders


TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma.

Behavioural brain disorders such as opioid and alcohol abuse, binge eating disorder, anxiety and fatigue affect more than 50 million people worldwide.  TheraCryf’s mission is to develop and partner novel medicines to significantly improve the lives of people with these debilitating conditions and help them enjoy life.
About us
Hexagon-pattern

Our Pipeline

TheraCryf is focused on developing commercially successful products. We are developing innovative therapeutics in brain disorders focusing on neuropsychiatry with a legacy programme in glioblastoma.
Read more +

Ox-1 - Substance Use Disorders (SUDs) / Anxiety

TheraCryf has a candidate stage antagonist molecule targeting the orexin-1 receptor with high specificity. This provides a potential treatment for addictive behaviours and anxiety.

Ox-1 is at late pre-clinical stage and is now funded through to readiness for regulatory submissions to start Phase 1 human volunteer studies.

DAT - Fatigue and Narcolepsy

The Company has a candidate stage atypical inhibitor of the brain dopamine transporter mechanism with potential utility in alleviating central fatigue and reducing the impact of the orphan condition narcolepsy.

DAT is also at a well-advanced preclinical stage and will be advanced into the clinic when additional resources become available.

SFX-01 and glioblastoma

Glioblastoma is a stage 4 malignant glioma representing 45% of all cases. Pre-clinical models show positive data for SFX-01 on tumour shrinkage and extended survival times.

TheraCryf is working in collaboration with Erasmus Medical Centre Rotterdam, NL on a fully grant funded programme to bring SFX-01 to patients with glioblastoma.

Strategy

TheraCryf’s strategy is to demonstrate proof of concept for its proprietary drug candidates in carefully selected diseases and then conclude partnerships with larger organisations better positioned to take these drugs through large scale clinical trials and commercial launch.
Read more

Science

TheraCryf's class-leading orexin-1 antagonist is being developed towards readiness for human clinical trials. A key pre-clinical experiment shows that TheraCryf's formulation can reduce bingeing behaviour without affecting normal eating and has been designed to overcome side effects prevalent in other orexin-1 blocker programmes.
Read more

Meet the team

TheraCryf’s leadership team has decades of corporate, financial and scientific experience in biotech and pharma companies. The Company is also supported by an expert Scientific Advisory Board.
Read more

News & Media

Read about TheraCryf’s developments in our regulatory news and latest media articles.
Read more

Resources

Find out more by viewing our corporate documents, presentations and scientific publications.
Read more